Ibere Pharmaceuticals (UNQ: IBER)
Financials · Capital Markets · US
$—
— today · — 1Y
Ibere Pharmaceuticals (UNQ: IBER) operates in the Capital Markets industry within the Financials sector.
Tweenvest scores Ibere Pharmaceuticals across four factors: quality 9/100. Its strongest factor is quality.
IBER price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- 0.36
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- —
- Next earnings
- —
About Ibere Pharmaceuticals
Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.
- Founded
- 2020
- Exchange
- Unquoted Security
- Currency
- USD
Other Capital Markets companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETFARCA: VTI | $2.31T | $378.15 | +0.29% |
| Vanguard Index Funds - Vanguard S&P 500 ETFARCA: VOO | $1.67T | $704.02 | +0.31% |
| iShares Trust - iShares Core S&P 500 ETFARCA: IVV | $892.30B | $769.62 | +0.32% |
| State Street SPDR S&P 500 ETF TrustARCA: SPY | $811.28B | $765.91 | +0.32% |
| Invesco QQQ Trust, Series 1NasdaqGM: QQQ | $483.79B | $710.72 | +0.62% |
| Vanguard Index Funds - Vanguard Morningstar Growth ETFARCA: VUG | $377.81B | $87.40 | +0.54% |
| Morgan StanleyNYSE: MS | $340.45B | $216.77 | +1.26% |
| The Goldman Sachs Group, Inc.NYSE: GS | $320.59B | $1,058.88 | +2.18% |
Figures last refreshed Aug 18, 2026.